stockrowKymera Therapeutics, Inc.
KYMR Healthcare Biotechnology
Kymera Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $39.2 million, down 16.7% from fiscal 2024.
- Revenue
- +466.4%
- EPS
- −40.3%
- Free cash flow
- −186.6%
- Total debt
- −66.6%
Quarter to September 2026, against a year earlier
Follow KYMR
Alert me
Kymera Therapeutics, Inc. (KYMR) Net income
Kymera Therapeutics, Inc.'s net income for fiscal 2025 was −$311.4M, compared with −$223.9M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$349.4M. Over the past ten years it has ranged from −$311.4M (fiscal 2025) to $0.00 (fiscal 2017) — the current reading is the lowest in ten years. Kymera Therapeutics, Inc. ranks 566th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$311.4M | — |
| FY2024 | −$223.9M | — |
| FY2023 | −$147.0M | — |
| FY2022 | −$154.8M | — |
| FY2021 | −$100.2M | — |
| FY2020 | −$45.6M | — |
| FY2019 | −$41.2M | — |
| FY2018 | −$21.5M | — |
| FY2017 | $0.00 | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | −$132.0M | — |
| Jun 2026 | −$61.2M | — |
| Mar 2026 | −$69.2M | — |
| Dec 2025 | −$87.0M | — |
| 25 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| TGTX TG Therapeutics, Inc. compare | $441.5M |
| TECH Bio-Techne Corp compare | $181.9M |
| CAI Caris Life Sciences,�Inc. compare | $96.1M |
| BMRN BioMarin Pharmaceutical Inc. compare | −$19.1M |
| TWST Twist Bioscience Corporation compare | −$136.7M |
| KYMR Kymera Therapeutics, Inc. | −$349.4M |
| SMMT Summit Therapeutics PLC compare | −$856.1M |
| IBRX ImmunityBio, Inc. compare | −$992.4M |
| PCVX Vaxcyte, Inc. compare | −$1.1B |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on KYMR
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement